Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "chronic inflammatory disease" wg kryterium: Temat


Wyświetlanie 1-2 z 2
Tytuł:
Multiple sclerosis and pregnancy – treatment considerations
Autorzy:
Kamieniak, M.P.
Wolanin, N.
Jarosz, P.
Kobialka, I.
Kosmider, K.
Petit, V.
Rejdak, K.
Powiązania:
https://bibliotekanauki.pl/articles/2098207.pdf
Data publikacji:
2020
Wydawca:
Instytut Medycyny Wsi
Tematy:
multiple sclerosis
chronic inflammatory disease
pregnancy
neurology
gynaecology
treatment
Opis:
Multiple sclerosis is a chronic inflammatory disease which, due to the destruction of the fibres of the central nervous system in the process of demyelination, leads to numerous neurological symptoms and progressive disability. The disease is autoimmune, which means that myelin is destroyed by the patient’s own cells, caused by improper functionong and regulation of the immune system. Multiple sclerosis affects more and more people and is therefore a significant clinical problem which, to a large Entent, affects women, especially in childbearing age This presents a big challenge for carrying out pregnancy while continuing the therapy, ensuring the safety of the foetus and simultaneously achieving the best possible therapeutic effect. The decision whether the therapy should be continued or whether it should be eliminatedis usually made according to assessment of the possible gains and losse. Despite the lack of clear indications, there are many studies proving the relative safety of the use of individual but not all the drugs during pregnancy. Pregnancy, however, has a fairly good impact on the development of multiple sclerosis, and that safety considerations, especially those concerning the growing foetus, force a decision to change or completely suspend the therapy. In-depth research on the already available and emerging therapeutic pathways in multiple sclerosis bring hope for increasingly better results in the future in the treatment of pregnant patients with multiple sclerosis.
Źródło:
Journal of Pre-Clinical and Clinical Research; 2020, 14, 4; 126-129
1898-2395
Pojawia się w:
Journal of Pre-Clinical and Clinical Research
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Atopic eczema: genetics or environment?
Autorzy:
Wuthrich, B
Cozzio, A.
Roll, A.
Senti, G.
Kundig, T.
Schmid-Grendelmeier, P.
Powiązania:
https://bibliotekanauki.pl/articles/49593.pdf
Data publikacji:
2007
Wydawca:
Instytut Medycyny Wsi
Tematy:
inflammatory skin disease
environmental factor
food
atopy patch test
non-atopic eczema
Staphylococcus aureus
contact allergen
chronic disease
human disease
genetic condition
therapy
Malassezia sympodialis
skin disease
immunological deviation
atopic eczema
skin structure
skin infection
skin barrier
Opis:
Atopic eczema (AE) is a multifactorial skin disease caused by a variety of factors such as genetic conditions, alterated skin structure, immunologic deviations and environmental factors, among others. There are two main subtypes of AE, i.e. the IgE-associated (“atopic eczema”) and the non-IgE-associated type (“nonatopic eczema”) with different prognosis concerning the development of respiratory diseases (“atopy march”). Recently, it was demonstrated that Filaggrin (= fi lament-aggregating protein, FL) is a major gene for atopic eczema. Filaggrin binds to and aggregates the keratin cytoskeleton in the epidermis. Homozygous FLG mutation leads to complete loss of fi laggrin expression in skin. Half or more of children with moderate to severe AE carry FLG mutations. Moreover, fi laggrin loss-of-function mutations predispose to phenotypes involved in the atopy march. The altered skin structure and a defi ciency in antimicrobial peptides favour colonization with Staphylococcus aureus and yeasts (Malassezia sp.). Sensitization to the yeast occurs almost exclusively in AE patients. S. aureus enterotoxins with superantigenic activity stimulate activation of T cells and macrophages. So far, AE skin lesions are orchestrated by the local tissue expression of proinfl ammatory cytokines and chemokines with activation of T lymphocytes, dendritic cells, macrophages, keratinocytes, mast cells, and eosinophils which lead to the skin infl ammatory responses. From the therapeutic point of view, besides emollients and local corticosteroids, topic immunomodulatory drugs (tacrolimus and pimecrolimus) have substantially improved the treatment of AE.
Źródło:
Annals of Agricultural and Environmental Medicine; 2007, 14, 2
1232-1966
Pojawia się w:
Annals of Agricultural and Environmental Medicine
Dostawca treści:
Biblioteka Nauki
Artykuł
    Wyświetlanie 1-2 z 2

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies